IMPACT THERAP-B (07630) has been included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect securities list.
Yinpai Pharmaceutical-B (07630) announced that, according to the announcements issued by the Shanghai Stock Exchange and Shenzhen Stock Exchange, the company's H shares have been included in the list of qualified securities for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, effective from September 7, 2026.
IMPACT THERAP-B (07630) announced that, according to the announcements issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange, the company's H shares have been included in the list of eligible securities for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from September 7, 2026.
Once the company's H shares are included in the list of eligible securities for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, qualified investors in mainland China will be able to directly invest in the company's H shares through the Shanghai Stock Exchange and Shenzhen Stock Exchange. The company believes that inclusion in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect will help further expand the company's investor base and is expected to enhance the liquidity of the company's H shares.
Related Articles
Beyond Zhihu (02390) financial reports: Reunderstanding the long-term value of a content community.
TECHTRONIC IND (00669) repurchased 50,000 shares for HKD 6.6845 million on September 7.
CHINA BOTON (03318) spent HKD 822,500 to buy back 278,000 shares on September 7.
Beyond Zhihu (02390) financial reports: Reunderstanding the long-term value of a content community.
TECHTRONIC IND (00669) repurchased 50,000 shares for HKD 6.6845 million on September 7.
CHINA BOTON (03318) spent HKD 822,500 to buy back 278,000 shares on September 7.
RECOMMEND
